HRP20240050T1 - Formulacije tpp1 i postupci liječenja bolesti cln2 - Google Patents
Formulacije tpp1 i postupci liječenja bolesti cln2 Download PDFInfo
- Publication number
- HRP20240050T1 HRP20240050T1 HRP20240050TT HRP20240050T HRP20240050T1 HR P20240050 T1 HRP20240050 T1 HR P20240050T1 HR P20240050T T HRP20240050T T HR P20240050TT HR P20240050 T HRP20240050 T HR P20240050T HR P20240050 T1 HRP20240050 T1 HR P20240050T1
- Authority
- HR
- Croatia
- Prior art keywords
- concentration
- rhtpp1
- preparation
- formulation
- sodium phosphate
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 11
- 238000009472 formulation Methods 0.000 title claims 10
- 102100035767 Adrenocortical dysplasia protein homolog Human genes 0.000 title 1
- 101000929940 Homo sapiens Adrenocortical dysplasia protein homolog Proteins 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 8
- 101000799476 Homo sapiens Tripeptidyl-peptidase 1 Proteins 0.000 claims 6
- LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 claims 4
- 229940052299 calcium chloride dihydrate Drugs 0.000 claims 4
- PYLIXCKOHOHGKQ-UHFFFAOYSA-L disodium;hydrogen phosphate;heptahydrate Chemical compound O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O PYLIXCKOHOHGKQ-UHFFFAOYSA-L 0.000 claims 4
- 229940050906 magnesium chloride hexahydrate Drugs 0.000 claims 4
- DHRRIBDTHFBPNG-UHFFFAOYSA-L magnesium dichloride hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[Cl-].[Cl-] DHRRIBDTHFBPNG-UHFFFAOYSA-L 0.000 claims 4
- 239000001103 potassium chloride Substances 0.000 claims 4
- 235000011164 potassium chloride Nutrition 0.000 claims 4
- 239000011780 sodium chloride Substances 0.000 claims 4
- BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 claims 4
- 230000035790 physiological processes and functions Effects 0.000 claims 3
- 208000002537 Neuronal Ceroid-Lipofuscinoses Diseases 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 230000006870 function Effects 0.000 claims 2
- 201000008051 neuronal ceroid lipofuscinosis Diseases 0.000 claims 2
- 230000006866 deterioration Effects 0.000 claims 1
- 230000004438 eyesight Effects 0.000 claims 1
- 230000035611 feeding Effects 0.000 claims 1
- 238000000185 intracerebroventricular administration Methods 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 230000007659 motor function Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/485—Exopeptidases (3.4.11-3.4.19)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
- C12Y304/14009—Tripeptidyl-peptidase I (3.4.14.9)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
Claims (11)
1. Formulacija koja sadržava rekombinantnu humanu tripeptidil peptidazu-1 (rhTPP1) za intracerebroventrikularnu, intratekalnu ili intraokularnu primjenu, naznačena time što rhTPP1 sadrži aminokiselinsku sekvencu SEQ ID NO: 1 ili njezin fragment, pri čemu formulacija sadrži rhTPP1 u koncentraciji od 25 mg/mL do 35 mg/mL, te nadalje sadrži kalijev klorid u koncentraciji od 0,01 mg/mL do 1 mg/mL, magnezijev klorid heksahidrat u koncentraciji od 0,01 mg/mL do 1 mg/mL, i kalcijev klorid dihidrat u koncentraciji od 0,01 mg/mL do 1 mg/mL, i pri čemu formulacija ima pH vrijednost od 6,5.
2. Formulacija prema zahtjevu 1, naznačena time što nadalje sadrži natrijev fosfat dvobazični heptahidrat u koncentraciji od 0,01 mg/mL do 1 mg/mL, natrijev fosfat monobazični monohidrat u koncentraciji od 0,01 mg/mL do 1 mg/mL, i natrijev klorid u koncentraciji od 1 mg/mL do 20 mg/mL.
3. Formulacija prema zahtjevu 1, naznačena time što sadrži natrijev fosfat dvobazični heptahidrat u koncentraciji od 0,11 mg/mL, natrijev fosfat monobazični monohidrat u koncentraciji od 0,08 mg/mL, natrijev klorid u koncentraciji od 8,77 mg/mL, kalijev klorid u koncentraciji od 0,22 mg/mL, magnezijev klorid heksahidrat u koncentraciji od 0,16 mg/mL, i kalcijev klorid dihidrat u koncentraciji od 0,21 mg/mL.
4. Formulacija prema bilo kojem od zahtjeva 1-3 naznačena time što je formulacija bez konzervansa.
5. Pripravak koji sadrži formulaciju prema bilo kojem od zahtjeva 1-4 naznačen time što što je za upotrebu za liječenje neuronalne ceroidne lipofuscinoze (CLN2).
6. Pripravak za upotrebu prema zahtjevu 5, naznačen time što pripravak sadrži dozu od 300 mg rekombinantne humane tripeptidil peptidaze-1 (rhTPP1).
7. Pripravak za upotrebu prema zahtjevu 5, naznačen time što se doza rekombinantne humane tripeptidil peptidaze-1 (rhTPP1) daje subjektu tijekom razdoblja od 4 sata.
8. Pripravak za upotrebu prema zahtjevu 5, naznačen time što se doza rekombinantne humane tripeptidil peptidaze-1 (rhTPP1) daje subjektu brzinom manjom ili jednakom 75 mg/sat.
9. Pripravak koji sadrži rekombinantnu humanu tripeptidil peptidazu-1 (rhTPP1) za primjenu u liječenju neuronalne ceroidne lipofuscinoze (CLN2) kod subjekta koji sadrži dozu rekombinantne humane tripeptidil peptidaze-1 (rhTPP1) djelotvornu da održi fiziološku funkciju ili uspori ili smanji pogoršanje fiziološke funkcije kod subjekta, pri čemu je fiziološka funkcija jezična funkcija, motorička funkcija, vid ili funkcija hranjenja, pri čemu rhTPP1 sadrži aminokiselinsku sekvencu SEQ ID NO: 1 ili njezin fragment, te pri čemu pripravak sadrži rhTPP1 u koncentraciji od 25 mg/mL do 35 mg/mL, te nadalje sadrži kalijev klorid u koncentraciji od 0,01 mg/mL do 1 mg/mL, magnezijev klorid heksahidrat u koncentraciji od 0,01 mg/mL do 1 mg/mL, i kalcijev klorid dihidrat u koncentraciji od 0,01 mg/mL do 1 mg/mL, te pri čemu formulacija ima pH vrijednost od 6,5.
10. Pripravak za upotrebu prema zahtjevu 9, naznačen time što pripravak nadalje sadrži natrijev fosfat dvobazični heptahidrat u koncentraciji od 0,01 mg/mL do 1 mg/mL, natrijev fosfat monobazični monohidrat u koncentraciji od 0,01 mg/mL do 1 mg/mL, i natrijev klorid u koncentraciji od 1 mg/mL do 20 mg/mL.
11. Pripravak za upotrebu prema zahtjevu 9, naznačen time što pripravak sadrži natrijev fosfat dvobazični heptahidrat u koncentraciji od 0,11 mg/mL, natrijev fosfat monobazični monohidrat u koncentraciji od 0,08 mg/mL, natrijev klorid u koncentraciji od 8,77 mg/mL, kalijev klorid u koncentraciji od 0,22 mg/mL, magnezijev klorid heksahidrat u koncentraciji od 0,16 mg/mL, i kalcijev klorid dihidrat u koncentraciji od 0,21 mg/mL.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562158789P | 2015-05-08 | 2015-05-08 | |
| US201662300171P | 2016-02-26 | 2016-02-26 | |
| PCT/US2016/031074 WO2016182862A1 (en) | 2015-05-08 | 2016-05-05 | Tpp1 formulations and methods for treating cln2 disease |
| EP16793229.2A EP3294345B1 (en) | 2015-05-08 | 2016-05-05 | Tpp1 formulations and methods for treating cln2 disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20240050T1 true HRP20240050T1 (hr) | 2024-03-29 |
Family
ID=57222195
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171905AA HRP20171905B1 (hr) | 2015-05-08 | 2016-05-05 | Formulacije tpp1 i postupci liječenja bolesti cln2 |
| HRP20240050TT HRP20240050T1 (hr) | 2015-05-08 | 2016-05-05 | Formulacije tpp1 i postupci liječenja bolesti cln2 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171905AA HRP20171905B1 (hr) | 2015-05-08 | 2016-05-05 | Formulacije tpp1 i postupci liječenja bolesti cln2 |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US10279015B2 (hr) |
| EP (2) | EP3294345B1 (hr) |
| JP (3) | JP6931330B2 (hr) |
| KR (1) | KR102375051B1 (hr) |
| CN (2) | CN107847615B (hr) |
| AU (1) | AU2016262434B2 (hr) |
| BR (1) | BR112017023805A2 (hr) |
| CA (1) | CA2984448A1 (hr) |
| CL (1) | CL2017002825A1 (hr) |
| DK (1) | DK3294345T3 (hr) |
| ES (1) | ES2968375T3 (hr) |
| FI (1) | FI3294345T3 (hr) |
| HR (2) | HRP20171905B1 (hr) |
| HU (1) | HUE065649T2 (hr) |
| IL (3) | IL299024A (hr) |
| LT (1) | LT3294345T (hr) |
| MX (1) | MX2017014204A (hr) |
| PL (1) | PL3294345T3 (hr) |
| PT (1) | PT3294345T (hr) |
| RS (1) | RS65101B1 (hr) |
| RU (1) | RU2733464C2 (hr) |
| SI (1) | SI3294345T1 (hr) |
| SM (1) | SMT202400026T1 (hr) |
| TW (1) | TWI752907B (hr) |
| WO (1) | WO2016182862A1 (hr) |
| ZA (1) | ZA201707373B (hr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI752907B (zh) * | 2015-05-08 | 2022-01-21 | 美商拜奧馬林製藥公司 | 用於治療cln2疾病之tpp1調配物及方法 |
| WO2018187385A1 (en) | 2017-04-03 | 2018-10-11 | The Regents Of The University Of California | Compositions and methods of diagnosing pancreatic cancer |
| EP3684463B1 (en) | 2017-09-19 | 2025-05-14 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement |
| US11717686B2 (en) | 2017-12-04 | 2023-08-08 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to facilitate learning and performance |
| US11273283B2 (en) | 2017-12-31 | 2022-03-15 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to enhance emotional response |
| US12280219B2 (en) | 2017-12-31 | 2025-04-22 | NeuroLight, Inc. | Method and apparatus for neuroenhancement to enhance emotional response |
| US11364361B2 (en) | 2018-04-20 | 2022-06-21 | Neuroenhancement Lab, LLC | System and method for inducing sleep by transplanting mental states |
| WO2020056418A1 (en) | 2018-09-14 | 2020-03-19 | Neuroenhancement Lab, LLC | System and method of improving sleep |
| US11786694B2 (en) | 2019-05-24 | 2023-10-17 | NeuroLight, Inc. | Device, method, and app for facilitating sleep |
| WO2020247952A2 (en) * | 2019-06-07 | 2020-12-10 | The Regents Of The University Of California | Systems comprising substrates and methods of using the same for detection of pancreatic cancers |
| CA3152521A1 (en) * | 2019-08-29 | 2021-03-04 | Biomarin Pharmaceutical Inc. | Methods for treating cln2 disease in pediatric subjects |
| IT201900023142A1 (it) * | 2019-12-05 | 2021-06-05 | Sifi Spa | Composizione topica oculare contenente metaboliti della fermentazione di lactobacillus |
| US20230060797A1 (en) * | 2021-09-02 | 2023-03-02 | Jcr Pharmaceuticals Co., Ltd. | Therapeutic compound for neuronal ceroid lipofuscinosis |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6302685B1 (en) | 1997-09-16 | 2001-10-16 | University Of Medicine And Dentistry Of New Jersey | Human lysosomal protein and methods of its use |
| US20020006400A1 (en) * | 2000-05-11 | 2002-01-17 | Peter Lobel | Recombinant human CLN2 protein and methods of its production and use |
| WO2002094176A2 (en) * | 2001-05-18 | 2002-11-28 | Solvay Pharmaceuticals Gmbh | Use of compounds with combined nep/mp-inhibitory activity on the preparation of medicaments |
| US20050130117A1 (en) * | 2001-10-03 | 2005-06-16 | Davis Cong L. | Modulators of lymphocyte activation and migration |
| CA2388659A1 (en) * | 2002-05-31 | 2003-11-30 | Mcgill University | Phospholipase a2 expression and activity and use thereof for diagnosis, prognostication, prevention and treatment of neural inflammatory and demyelinating disease |
| US7442372B2 (en) | 2003-08-29 | 2008-10-28 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
| WO2008049058A2 (en) * | 2006-10-18 | 2008-04-24 | Cornell Research Foundation, Inc. | Cln2 treatment of alzheimer's disease |
| WO2008157308A2 (en) * | 2007-06-13 | 2008-12-24 | Wayne State University Board Of Governors | A zwitterion solution for low-volume therapeutic delivery |
| EP2333074A1 (en) * | 2009-12-14 | 2011-06-15 | Robert Steinfeld | Substances and methods for the treatment of lysosmal storage diseases |
| WO2012015910A2 (en) * | 2010-07-28 | 2012-02-02 | Allon Therapeutics Inc. | Use of adnf polypeptides for treating neurodegenerative diseases |
| CN103906528A (zh) * | 2011-06-24 | 2014-07-02 | 安米林药品有限责任公司 | 用glp-1受体激动剂的缓释制剂治疗糖尿病的方法 |
| US20150000936A1 (en) * | 2011-12-13 | 2015-01-01 | Schlumberger Technology Corporation | Energization of an element with a thermally expandable material |
| WO2013096899A2 (en) | 2011-12-23 | 2013-06-27 | Shire Human Genetic Therapies, Inc. | Stable formulations for cns delivery of arylsulfatase a |
| TWI626250B (zh) * | 2012-11-27 | 2018-06-11 | 拜奧馬林製藥公司 | 靶向治療性溶小體酶融合蛋白及其用途 |
| WO2014089449A1 (en) | 2012-12-07 | 2014-06-12 | Rush University Nedical Center | Composition and method for treating neuronal ceroid lipofuscinosis |
| AU2014293460B2 (en) * | 2013-07-26 | 2019-10-24 | University Of Iowa Research Foundation | Methods and compositions for treating brain diseases |
| TWI752907B (zh) * | 2015-05-08 | 2022-01-21 | 美商拜奧馬林製藥公司 | 用於治療cln2疾病之tpp1調配物及方法 |
-
2016
- 2016-04-27 TW TW105113155A patent/TWI752907B/zh active
- 2016-05-05 CA CA2984448A patent/CA2984448A1/en active Pending
- 2016-05-05 FI FIEP16793229.2T patent/FI3294345T3/fi active
- 2016-05-05 EP EP16793229.2A patent/EP3294345B1/en active Active
- 2016-05-05 PL PL16793229.2T patent/PL3294345T3/pl unknown
- 2016-05-05 HR HRP20171905AA patent/HRP20171905B1/hr active IP Right Grant
- 2016-05-05 PT PT167932292T patent/PT3294345T/pt unknown
- 2016-05-05 SM SM20240026T patent/SMT202400026T1/it unknown
- 2016-05-05 AU AU2016262434A patent/AU2016262434B2/en active Active
- 2016-05-05 RU RU2017142727A patent/RU2733464C2/ru active
- 2016-05-05 RS RS20240067A patent/RS65101B1/sr unknown
- 2016-05-05 MX MX2017014204A patent/MX2017014204A/es unknown
- 2016-05-05 HU HUE16793229A patent/HUE065649T2/hu unknown
- 2016-05-05 BR BR112017023805-5A patent/BR112017023805A2/pt active IP Right Grant
- 2016-05-05 LT LTEPPCT/US2016/031074T patent/LT3294345T/lt unknown
- 2016-05-05 EP EP23204139.2A patent/EP4327873A3/en active Pending
- 2016-05-05 WO PCT/US2016/031074 patent/WO2016182862A1/en active Application Filing
- 2016-05-05 JP JP2017558434A patent/JP6931330B2/ja active Active
- 2016-05-05 CN CN201680025984.6A patent/CN107847615B/zh active Active
- 2016-05-05 CN CN202210014711.9A patent/CN114225018A/zh active Pending
- 2016-05-05 ES ES16793229T patent/ES2968375T3/es active Active
- 2016-05-05 HR HRP20240050TT patent/HRP20240050T1/hr unknown
- 2016-05-05 IL IL299024A patent/IL299024A/en unknown
- 2016-05-05 US US15/147,485 patent/US10279015B2/en active Active
- 2016-05-05 SI SI201631792T patent/SI3294345T1/sl unknown
- 2016-05-05 KR KR1020177032973A patent/KR102375051B1/ko active Active
- 2016-05-05 DK DK16793229.2T patent/DK3294345T3/da active
-
2017
- 2017-10-29 IL IL255307A patent/IL255307B/en active IP Right Grant
- 2017-10-30 ZA ZA2017/07373A patent/ZA201707373B/en unknown
- 2017-11-08 CL CL2017002825A patent/CL2017002825A1/es unknown
-
2019
- 2019-03-28 US US16/368,091 patent/US10758598B2/en active Active
-
2020
- 2020-04-12 IL IL273913A patent/IL273913B2/en unknown
- 2020-07-28 US US16/941,454 patent/US11229687B2/en active Active
-
2021
- 2021-08-13 JP JP2021131875A patent/JP7421520B2/ja active Active
-
2024
- 2024-01-12 JP JP2024003133A patent/JP2024026739A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20240050T1 (hr) | Formulacije tpp1 i postupci liječenja bolesti cln2 | |
| ES2911207T3 (es) | Composiciones de insulina de acción rápida | |
| JP6849433B2 (ja) | ケルセチン配糖体を含有する筋萎縮抑制剤 | |
| HRP20191966T1 (hr) | Stabilizirani neproteinski klostridijalni pripravci toksina | |
| HRP20191285T1 (hr) | Predlijekovi karbidopa i l-dopa te njihova uporaba za liječenje parkinsonove bolesti | |
| JP2015147773A5 (hr) | ||
| JP2015527402A5 (hr) | ||
| HRP20171256T1 (hr) | Farmaceutski pripravci karbetocina | |
| IL173684A0 (en) | Disodium-4,4'-azo-bis-salicylate and pharmaceutical compositions containing the same | |
| Moslemi et al. | Oral zinc sulphate and prevention of radiation-induced oropharyngealmucositis in patients with head and neck cancers: a double blind, randomized controlled clinical trial | |
| ES2982123T3 (es) | Agente para la inmunomodulación de apoyo que contiene ácido propiónico y éster de ácido fumárico | |
| JP2017535616A5 (hr) | ||
| HRP20191854T1 (hr) | Orodisperzibilni dezmopresin za povećanje početnog razdoblja sna neometanog s nokturijom | |
| JP2017533972A5 (hr) | ||
| CA2986891C (en) | Compositions for use in treating parkinson's disease and related disorders | |
| HRP20230300T1 (hr) | Kombinacije imetelstata i venetoklaksa za liječenje akutne mijeloidne leukemije | |
| JP2020500864A5 (hr) | ||
| HRP20180468T1 (hr) | Novi derivat analoga inzulina | |
| HRP20210010T1 (hr) | Injekcijske farmaceutske formulacije lefamulina | |
| BR112019004210A2 (pt) | composição farmacêutica, método e kit para tratamento da deficiência de hormônio do crescimento | |
| PH12015502005B1 (en) | New stable pentadecapeptide salts, a process for preparation thereof, a use thereof in the manufacture of pharmaceutical preparations and a use thereof in therapy | |
| HRP20220407T1 (hr) | Pripravci i postupci za uporabu u liječenju homocistinurije | |
| RU2016137926A (ru) | Композиции грапипранта и способы их применения | |
| JP2019529569A5 (hr) | ||
| RU2016121401A (ru) | Устойчивые при хранении лиофилизованные составы трипептидов |